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doi:10.1016/j.jmii.2010.08.011Background: Cryptococcosis is a systemic infection caused by Cryptococcus neoformans, and
cryptococcal meningitis can occur in patients with late-stage human immunodeficiency virus
(HIV) infection and other forms of immunosuppressive status. This study was designed to
compare clinical features and laboratory findings of cryptococcal meningitis in HIV-positive
and HIV-negative patients.
Methods: From January 1, 2000 to December 31, 2009, all patients aged more than 18 years
hospitalized at National Taiwan University Hospital with a diagnosis of cryptococcal meningitis
were analyzed retrospectively.
Results: In total, 88 patients with cryptococcal meningitis were identified and 37 (42%) were
HIV infected. Cryptococcal meningitis occurred in young (mean, 38 vs. 60; p < 0.001) and male
(97% vs. 63%, p < 0.001) populations more frequently among HIV-positive group with higher
Charlson comorbidity score (mean, 7 vs. 4; p < 0.001), higher initial complaint of cough
(36% vs. 16%; p Z 0.032), lower cerebrospinal fluid (CSF) white count (mean, 26 vs. 86;
p Z 0.024), lower total protein of the CSF (mean, 88 vs. 149; p Z 0.012), higher percentage
of serum latex agglutination cryptococcal antigen titer exceeding 1:512 (77% vs. 50%;
p Z 0.026), more extraneural involvement (70% vs. 49%; p Z 0.046), more cryptococcemia
(68% vs. 35%; p Z 0.003), and higher proportion of normal brain images (44% vs. 13%;
p Z 0.003) than HIV-negative group. The all-cause mortality rates on Day 30 and Day 90 were
23.9% and 31.8%, respectively. The independent risk factors for Day 30 mortality were altered
mental status, extraneural involvement, absence of lymphocyte predominance, and absence
of leptomeningeal enhancement (odds ratio: 7.84, 9.71, 0.22, and 0.07, respectively; 95%
confidence interval): 2.03e30.27, 2.01e46.94, 0.06e0.80, and 0.01e0.49, respectively).
Those for Day 90 mortality were serum white count more than 11,000/mL, higher Charlsonof Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Taipei 100,
il.com (Y.-C. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Comparisons of clinical features and mortality of cryptococcal meningitis 339comorbidity score, and absence of normal brain images (odds ratio: 5.39, 1.40, and 0.09,
respectively; 95% confidence interval: 1.22e23.72, 1.11e1.76, and 0.01e0.78, respectively).
Conclusions: The clinical features of cryptococcal meningitis between HIV and non-HIV
patients have some divergences, including age, sex, underlying diseases, CSF parameters, ex-
traneural site involvement, fungemia, and so on. We also identified risk factors for mortality of
this disease. However, the mortality of cryptococcal meningitis was not different in HIV-posi-
tive and HIV-negative patients in terms of Day 30 and Day 90 mortality.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cryptococcosis is a systemic infection caused by Crypto-
coccus neoformans, an encapsulated yeast-like organism
that can be isolated from the environment. Cryptococcal
meningitis is a common opportunistic infection and
acquired immunodeficiency syndrome (AIDS)-defining
illness in patients with late-stage human immunodeficiency
virus (HIV) infection, particularly in Southeast Asia and
Southern and East Africa.1,2 Cryptococcal meningitis also
occurs in patients with other forms of immunosuppression,
including corticosteroids use, organ transplantations,
chronic leukemias, lymphomas and sarcoidosis,3 and in
apparently immunocompetent individuals.4 Although the
natural history of cryptococcal meningitis in patients with
AIDS had been well documented in developed countries,5e7
there were few updated publications about cryptococcal
meningitis in HIV-negative patients. We hypothesize that
patient characteristics, clinical features, and outcomes of
cryptococcal meningitis in HIV-positive patients may be
different from those in HIV-negative patients. In this
retrospective study, we aimed to compare the clinical
presentations, laboratory data, radiographic findings, and
outcomes of cryptococcal meningitis between HIV-positive
and HIV-negative patients who were admitted to a univer-
sity hospital from 2000 to 2009.
Patients and methods
Study population
We retrospectively reviewed the medical and microbiolog-
ical records of hospitalized patients aged 18 years or older
with a diagnosis of cryptococcal meningitis from 2000 to
2009. Cryptococcal meningitis was defined as positive
cerebrospinal fluid (CSF) culture for C neoformans.
All enrolled patients were divided into HIV-positive and
HIV-negative groups. A standardized case collection form
was used to record age, sex, underlying diseases, Charlson
comorbidity score, initial presentations, duration of initial
symptoms to diagnosis, laboratory data, radiographic findings,
and intrahospital mortality. Factors that would predict a poor
outcome were also evaluated between these two groups.
Laboratory studies
HIV infection was detected by positive enzyme-linked
immunosorbent assay method (Abbott Axsym System,Wiesbaden, Germany) and confirmed by Western blotting
(NEW LAV Blot, Bio-rad, Marnes-la-Coquette, France). CSF
was routinely sent for complete white blood cell counts and
differential counts, glucose, protein, and India ink stain and
cultures. Urine, pus, lung, ascites, pleural effusion, lymph
node, and/or other biopsy tissues and aspiration specimens
were performed and submitted for cultures when indi-
cated. Brain imaging, including computed tomography (CT)
or magnetic resonance imaging (MRI) was done when
indicated and the results were reviewed. Neuroimage
findings included leptomeningeal enhancement, cerebral
infarction, hydrocephalus, abscess, and other presenta-
tions. The serum and CSF cryptococcal antigen titers were
determined using commercial latex agglutination tests
(LATEX-CRYPTOCOCCUS ANTIGEN DETECTION SYSTEM,
Immuno-Mycologics, Inc., Norman, USA).
Treatment strategies and outcome
Amphotericin B, 0.7e1 mg/kg/d, was the drug of choice in
both HIV-positive and HIV-negative patients with crypto-
coccal meningitis.8 Flucytosine was not available at
National Taiwan University Hospital (NTUH) until 2008, so
our treatment strategies were as follows: the first anti-
fungal agent chosen was amphotericin B and at least 1 week
of duration was prescribed.
Beside, time to sterile CSF, the duration from positive
culture for C neoformans to mortality, and the period of
starting antifungal agents after presentation at NTUH were
all recorded for analysis of treatment outcomes, defined by
all-cause mortality on Day 30 and Day 90. The factors for
poor prognosis were included in the univariate and multi-
variate analyses.
Statistical analysis
Continuous variables were described as mean  standard
deviation and compared using Student’s t test. Categorical
variables were compared with a c2 test or Fisher exact test
if the expected values were below 10. Risk factors for all-
cause Day 30 and/or Day 90 mortality were identified using
a logistic regression model. All parameters were initially
tested by univariate analysis and those with a p value <0.05
were used for multivariate analysis. Parameters with
collinearity (tested by correlation matrix) were not simul-
taneously considered in the final model. Stepwise model
comparison and Akaike’s Information Criterion were used to
determine the best model of multiple variables analysis.
Statistical analyses were performed using SAS 9.1.3 (SAS
340 Y.-C. Lee et al.Institute, Cary, NC, USA). All tests were two-tailed and a p
value <0.05 was considered statistically significant.
Results
Patient population
From 2000 to 2009, 88 patients with cryptococcal meningitis
were identified. Of these 88 patients, 37 (42%) were HIV
infected. Comparisons of the demographic and clinical
features in the HIV-positive and HIV-negative groups are
shown in Table 1. Compared with HIV-uninfected patients,
HIV-infected patients were more likely to be male and
younger. Among HIV-negative group, 45 (91.8%) had at least
one underlying disease, and the most frequently recorded
underlying diseases included hepatobiliary diseases, hyper-
tension, hematology, and oncologic diseases (Table 1).
Although less underlying diseases are associated with HIV-
infected patients, higher percentage of these patients
present with Charlson comorbidity score above 6 (pZ 0.02).
There was no significant difference in initial presentations
between HIV-positive and HIV-negative patients, except
cough, which was more frequent in the former group (36% vs.
16%, p Z 0.03). The most commonly complained symptoms
were fever (67%), followed by headache (65%), and altered
mental status (43%). Other initial presentations include
hearing impairment, incoherent speech, and unilateral
decrease in muscle power. About 75% and 74% of the patients
were diagnosed as having cryptococcal meningitis in less than
1 month from the initial onset of symptoms in HIV-infected
and noneHIV-infected groups, respectively. Overall, the in-
hospital mortality was 29.7% and 33.3% in HIV-positive and
HIV-negative patients, respectively (pZ 0.720).
Laboratory data
The results of laboratory data and radiological findings are
also shown in Table 2. The mean CSF leukocyte count was
26 cells/mm3 inHIV-infected patients, whichwas significantly
lower than that in the noneHIV-infected group (86 cells/
mm3, p Z 0.02). About 83.8% of patients with HIV infection
had white count below 20 in CSF in contrast to 36% of patients
without HIV infection. Among HIV-positive patients, there
was significantly lower average total protein level in CSF
(88 mg/dL vs. 149 mg/dL, p Z 0.012) and fewer cases with
CSF glucose below 40 mg/dL (38.9% vs. 61.2%, p Z 0.042)
than those in HIV-negative patients. There was no statistical
difference in opening pressure on spinal tap between the two
groups. C neoformans was detected by India ink preparation
in 24 patients (of 35) with HIV infection and 21 of 42 patients
without HIV infection. In 67% (59 of 88) of the patients, blood
and CSF samples for cryptococcal Ag tests were collected
simultaneously and processed in parallel. CSF latex aggluti-
nation cryptococcal antigen titer (LACT) more than 1:512 in
HIV-positive and HIV-negative groups was demonstrated in 24
and 22 patients, respectively. A higher percentage of the
patients with HIV infection had serum LACT exceeding 1:512
than those without HIV infection (pZ 0.026). However, there
were three and two cases with LACT in CSF and serum less
than 1:8 for HIV-positive group, respectively, and four and
one patients for HIV-negative group, respectively. Twenty-sixof 37 patients among HIV-positive group and 25 of 51 patients
among HIV-negative group had C neoformans isolated from
specimens other than CSF, including blood (25 vs. 18), lung
specimens (3 vs. 4), urine (2 vs. 4), lymph node (1 vs. 0),
ascites (0 vs. 2), pleural effusion (0 vs. 1), andwound (0 vs. 1).
Brain images were performed in only 73 patients. The most
common presentations were cerebral infarction (30), lep-
tomeningeal enhancement (27), and hydrocephalus (11), but
17 patients had normal image findings. Higher percentage of
patients without HIV infection presented with cerebral
infarction than those with HIV infection (p Z 0.008), but
normal presentations were revealed in the HIV-positive group
significantly muchmore than HIV-negative group (pZ 0.003).Treatment and outcome
Thirty patients were treated with amphotericin B-based
therapy initially and 25 patients had received amphotericin
B for more than 1 week in HIV-positive group. Among non-
HIV cases, amphotericin B-based regimen was prescribed
initially in 29 patients and at least 1 week of treatment was
used in 93% (27 of 29) of these patients. The average days of
starting antifungal agents after arrival at the hospital were
2.6 days and 9.5 days in the HIV-infected group and non-HIV
group, respectively (p Z 0.012). Of the 31 HIV-infected
patients whose CD4 cell counts were determined, the count
was <100/mm3 in most cases (28 of 31, 90.3%), and the
average count was 41/mm3 (range, 2e267). About 68.8% (22
of 32) of these HIV-positive patients had plasma HIV viral
load above 105 copies/mL. The all-cause mortality rate on
Day 30 was 23.9% (21 deaths) and on Day 90 was 31.8% (28
deaths). There were 26 patients with HIV infection and
34 patients without HIV infection who survived. For those
survived, the mean duration of antifungal treatment to
sterile CSF was 18 days versus 14 days in the HIV-positive
group and the HIV-negative group without statistical
significance. In univariate analysis, factors associated
with mortality at Day 30 were CSF white count below
20 cells/mm3, absence of lymphocyte predominance,
higher Charlson comorbidity score, absence of headache,
altered mental status, cryptococcemia, extraneural
involvement, and absence of leptomeningeal enhancement
on brain images (Table 3). In multivariate analysis, absence
of lymphocyte predominance [odds ratio (OR) 0.22, 95%
confidence interval (CI): 0.06e0.80, p Z 0.022], altered
mental status (OR 7.84, 95% CI: 2.03e30.27, p Z 0.003),
extraneural involvement (OR 9.71, 95% CI: 2.01e46.94,
p Z 0.005), and absence of leptomeningeal enhancement
on brain images (OR 0.07, 95% CI: 0.01e0.49, p Z 0.007)
were found to be independent predictors of mortality at
Day 30. On the other hand, age above 50 years, absence of
lymphocyte predominance, initial serum white count more
than 11,000/mL, presence of hepatobiliary diseases, pres-
ence of renal diseases, higher Charlson comorbidity score,
absence of headache, dyspnea, cryptococcemia, extra-
neural involvement, and absence of normal brain images
had strong association with mortality at Day 90 in univariate
analysis (Table 4). The multivariate analysis demonstrated
that initial serum white count more than 11,000/mL (OR
5.39, 95% CI: 1.22e23.72, pZ 0.026), Charlson comorbidity
score (OR 1.40, 95% CI: 1.11e1.76, pZ 0.004), and absence
Table 1 Demographic and clinical features in HIV-positive and HIV-negative patients with Cryptococcus neoformansmeningitis
Variables HIV positive HIV negative p
N Z 37 N Z 51
Age, yr
Mean  SD 38.19  12.12 59.57  14.17
Range 23e81 31e88 <0.001
Sex (male, %) 36 (97.3%) 32 (62.7%) <0.001
Underlying diseases 37 49
Hepatobiliary diseases 2 (5.4%) 17 (34.7%) 0.001
Hypertension 1 (2.7%) 15 (30.6%) <0.001
Hematology and oncology 5 (13.5%) 14 (28.6%) 0.096
Diabetes mellitus 1 (2.7%) 12 (24.5%) 0.005
Neurological diseases 3 (8.1%) 12 (24.5%) 0.047
Autoimmune diseases 0 9 (18.4%) 0.009
Renal diseases 1 (2.7%) 8 (16.3%) 0.082
Respiratory diseases 3 (8.1%) 8 (16.3%) 0.426
Cardiovascular diseases 1 (2.7%) 5 (10.2%) 0.360
Endocrine diseases 0 3 (6.1%)
Others 0 5 (10.2%)
Nil 0 4 (8.2%)
Charlson comorbidity score 7  1.55 4  2.80 <0.001
>6 16 (43.2%) 10 (20.4%) 0.022
Initial presentation 36 50
Headache 24 (66.7%) 32 (64%) 0.798
Fever 28 (77.8%) 30 (60%) 0.083
Altered mental status 13 (36.1%) 24 (48%) 0.273
Vomiting 17 (47.2%) 14 (28%) 0.067
Unsteady gait 5 (13.9%) 11 (22%) 0.340
Cough 13 (36.1%) 8 (16%) 0.032
Stiff neck 6 (16.7%) 7 (14%) 0.733
Abnormal vision 4 (11.1%) 6 (12%) >0.999
Dyspnea 7 (19.4%) 6 (12%) 0.342
Seizure 4 (11.1%) 4 (8%) 0.897
Others 10 (27.8%) 10 (20%)
Duration of initial symptoms to diagnosis 36 50
1 mo 27 (75%) 37 (74%) 0.917
In-hospital mortality 11 (29.7%) 17 (33.3%) 0.720
HIV Z human immunodeficiency virus; SD Z standard deviation.
Neurological diseases included cerebrovascular diseases, hydrocephalus; autoimmune diseases, ankylosing spondylodiskitis, dermato-
myositis/polymyositis, systemic lupus erythematosus, Sjogren’s syndrome, microscopic polyangitis, autoimmune pancreatitis; respiratory
diseases, pulmonary tuberculosis, bronchiectasis, pneumoconiosis; cardiovascular diseases, sick sinus syndrome, cardiomyopathy,
arrhythmia, coronary artery diseases, valvular heart diseases; endocrine diseases, adrenal insufficiency, Graves’ disease; other underlying
diseases, transplant recipient, trisomy X.
Other initial presentations included hearing impairment, incoherent speech and unilateral decrease in muscle power, and memory
impairment.
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p Z 0.029) were independent risk factors for mortality at
Day 90 in cryptococcal meningitis. The Kaplan-Meier
survival curve for all 88 patients is showed in the Fig. 1,
which demonstrates no significant difference in mortality
hazard between HIV-infected and noneHIV-infected group
(Log-rank test, p Z 0.832).Discussion
Cryptococcal meningitis has been described as an oppor-
tunistic infection in immunocompromised patients, but is
also known to affect apparently healthy individuals.9 Of
the 88 patients identified with cryptococcal meningitis in
Table 2 Laboratory data and radiographic findings in HIV-positive and HIV-negative patients with Cryptococcus neoformans
meningitis
Variables HIV positive HIV negative p
N Z 37 N Z 51
CSF white blood cell count (median,
interquartile range, minimum-maximum),
cells/mm3
3 (8, 0e291) 43.5 (82, 0e1,100) <0.001
<20 31 (83.8%) 18 (36%) <0.001
Lymphocyte predominant 24 (64.9%) 35 (68.60%) 0.711
CSF protein (median, interquartile range,
minimum-maximum), mg/dL
59 (68.9, 0e443) 111 (133.4, 1e767.4) 0.003
>45 25 (67.6%) 41 (83.7%) 0.080
CSF glucose (mean  SD), mg/dL 46.22  24.39 36.02  26.73 0.075
<40 14 (38.9%) 30 (61.2%) 0.042
Open pressure (mean  SD), mmH2O 283.04  116.05 275.39  138.04 0.824
>200 23 (79.3%) 24 (64.9%) 0.199
CSF positive India ink 24/35 (68.6%) 21/42 (50%) 0.100
CSF LACT, >1:512 24/34 (70.6%) 22/41 (53.7%) 0.134
Serum LACT, >1:512 23/30 (76.7%) 18/36 (50%) 0.026
Serum white blood cell count (mean  SD), /mL 6236.29  6268.23 8,374  4386.63 0.056
>11,000 3 (8.1%) 8 (16%) 0.447
Serum sodium (mean  SD), mmol/L 135.82  6.95 134  8.05 0.274
Extraneural involvement 26 (70.3%) 25 (49%) 0.046
Fungemia 25 (67.6%) 18 (35.3%) 0.003
Brain images (CT or MRI) 25 48
Enhancement 11 (44%) 16 (33.3%) 0.370
Cerebral infarction 5 (20%) 25 (52.1%) 0.008
Hydrocephalus 2 (8%) 9 (18.8%) 0.387
Abscess 1 (4%) 1 (2.1%) >0.999
Others 7 (28%) 7 (14.6%)
Normal 11 (44%) 6 (12.5%) 0.003
CSFZ cerebrospinal fluid; CTZ computed tomography; HIVZ human immunodeficiency virus; LACTZ latex agglutination cryptococcal
antigen titer; MRI Z magnetic resonance imaging; SD Z standard deviation.
Extraneural involvement defined as C neoformans isolated from specimens other than CSF, including any one of the followings: blood,
lung specimens, urine, lymph node, ascites, pleural effusion, and wound.
Normal brain images on CT or MRI were defined as no obvious intracranial lesions demonstrated; other brain image findings included
encephalitis, gelatinous pseudocyst, brain edema, and hemorrhage.
342 Y.-C. Lee et al.the present study, 37 (42%) were documented with HIV
infection. In a series of 306 HIV-negative patients with
cryptococcosis, the predisposing conditions were steroids
(28%), organ transplant (18%), chronic organ failure (liver,
lung, kidney) (18%), malignancy (18%), and rheumatological
disease (13%).4 Shih et al.10 reported that 42 of 94 patients
with cryptococcal meningitis in noneHIV-infected status
had documented underlying diseases, including lymphoma
(12%), rheumatological diseases (11%), diabetes mellitus
(9%), transplantation (6%), cancers (6%), cirrhosis of the
liver (6%), and chronic renal failure (5%). We found that
there seemed to be higher proportion of patients with the
above predisposing conditions in recent years. Cryptococcal
meningitis affects people of any age and men are more
affected than women.11e13 The nationwide survey by the
French Cryptococcosis Study Group found that the male-to-
female ratio was much greater for HIV-infected patients
compared with those without HIV (8:1 vs. 1.7:1).14 HIV
affects mainly the young and sexually active.15 Charlson
comorbidity score was calculated in our study and wassignificantly higher in the HIV-positive group, probably
because of the inherent characteristics of the scoring
system.
Patients with cryptococcal meningitis commonly present
with a subacute or chronic course more than weeks to
months. In a 130-case study of patients with cryptococcal
meningoencephalitis, the duration of symptoms before
admission less than 1 month was 48% and 52% in AIDS and
non-AIDS group, respectively (p Z 0.599).11 Interestingly,
there was no difference in duration of initial symptoms to
diagnosis between these two groups in our study; 75% and
74% of the patients in HIV-positive and HIV-negative group,
respectively, were diagnosed within 1 month. This might
imply that accessibility to hospital care in Taiwan is very
convenient. Although less typical clinical manifestations of
cryptococcal meningitis in HIV-infected patients (such as
headache, altered mental status, and stiff neck) were
reported previously,5,6,16 no significant difference in the
above-mentioned presentations between both groups was
seen in our series.
Table 3 Factors associated with death at Day 30 in cryptococcal meningitis
Variables Univariate analysis Multivariate analysis
Odds ratio 95% CI p Odds ratio 95% CI p
Age (>50 yr) 1.78 0.65e4.84 0.261
India ink 1.16 0.39e3.40 0.793
CSF WBC < 20 cells/mm3 4.52 1.37e14.86 0.013
CSF Glu < 40 mg/dL 0.91 0.34e2.49 0.857
CSF TP > 45 mg/dL 0.50 0.17e1.49 0.430
CSF LACT, >1:512 2.10 0.67e6.63 0.206
Open pressure > 200 mmH2O 0.57 0.16e2.05 0.393
Lymphocyte predominant 0.33 0.12e0.92 0.034 0.22 0.06e0.80 0.022
Initial serum WBC > 11,000/mL 3.13 0.84e11.57 0.088
Hepatobiliary diseases 2.21 0.73e6.65 0.159
Renal diseases 2.82 0.68e11.69 0.152
HIV infection 1.35 0.50e3.61 0.554
Charlson comorbidity score 1.32 1.06e1.64 0.013
Headache 0.38 0.14e1.03 0.057
Fever 2.49 0.75e8.26 0.137
Altered mental status 3.65 1.29e10.33 0.015 7.84 2.03e30.27 0.003
Dyspnea 2.23 0.64e7.75 0.209
Cryptococcemia 4.74 1.55e14.48 0.006
Extraneural involvement 6.18 1.66e22.97 0.007 9.71 2.01e46.94 0.005
Leptomeningeal enhancement 0.18 0.04e0.82 0.027 0.07 0.01e0.49 0.007
CSFZ cerebrospinal fluid; CIZ confidence interval; GluZ glucose; HIVZ human immunodeficiency virus; LACTZ latex agglutination
cryptococcal antigen titer; TP Z total protein; WBC Z white blood cell.
Comparisons of clinical features and mortality of cryptococcal meningitis 343The CSF indices (cell count, protein, and glucose) were
almost always abnormal in HIV-negative patients with
cryptococcal meningitis whereas they may be normal or
only mildly abnormal in patients with AIDS,17,18 which were
consistent with our observations. Beside, the presentationTable 4 Factors associated with death at Day 90 in cryptococc
Variables Univariate analy
Odds ratio 95% CI
Age (>50 yr) 2.76 1.08e7.0
India ink 0.86 0.33e2.2
CSF WBC < 20 cells/mm3 2.04 0.80e5.2
CSF Glu < 40 mg/dL 0.81 0.32e2.0
CSF TP > 45 mg/dL 0.65 0.23e1.8
CSF LACT, >1:512 2.46 0.84e7.2
Open pressure > 200 mmH2O 0.52 0.17e1.6
Lymphocyte predominant 0.33 0.13e0.8
Initial serum WBC > 11,000/mL 4.58 1.22e17.2
Hepatobiliary diseases 3.02 1.06e8.6
Renal diseases 9.33 1.79e48.5
HIV infection 0.85 0.34e2.1
Charlson comorbidity score 1.32 1.08e1.6
Headache 0.30 0.12e0.7
Fever 1.70 0.62e4.6
Altered mental status 2.35 0.94e5.9
Dyspnea 4.24 1.24e14.5
Cryptococcemia 2.52 1e6.3
Extraneural involvement 3 1.11e8.1
Normal brain images 0.10 0.01e0.8
CSFZ cerebrospinal fluid; CIZ confidence interval; GluZ glucose; H
cryptococcal antigen titer; TP Z total protein; WBC Z white blood cof HIV-infected patients with C neoformans meningitis was
characterized by positive India ink smears, positive LACT of
CSF and serum, and the isolation of cryptococci from
extraneural sites,3,16,18 the former two indicating an
increased fungal load in all patients with cryptococcalal meningitis
sis Multivariate analysis
p Odds ratio 95% CI p
9 0.035
6 0.763
4 0.138
2 0.649
4 0.419
3 0.100
6 0.271
6 0.023
8 0.025 5.39 1.22e23.72 0.026
4 0.039
8 0.008
1 0.720
2 0.007 1.40 1.11e1.76 0.004
8 0.013
7 0.301
0 0.069
1 0.021
7 0.051
1 0.030
1 0.031 0.09 0.01e0.78 0.029
IVZ human immunodeficiency virus; LACTZ latex agglutination
ell.
Figure 1. Kaplan-Meier survival curve for cryptococcal
meningitis according to HIV infection status. HIV Z human
immunodeficiency virus.
344 Y.-C. Lee et al.meningitis.17,18 Indeed, our study confirmed that the
greater frequency in which C neoformans was isolated from
extraneural sites, including blood, in the HIV-positive group
was significant (p Z 0.046). Although there was no signifi-
cant difference in the India ink positivity between the two
groups (69% vs. 50% in HIV positive and HIV negative,
respectively), it might be because of small number of cases
in our study. In comparing the brain images of HIV-infected
and noneHIV-infected groups, the higher proportion of
normal images among HIV-positive patients in the present
study is compatible with previous reports.6,16,17 In contrast,
the scans of 87.5% of the 48 HIV-negative patients who
underwent brain CT or MRI were abnormal, with hydro-
cephalus being detected in 21.4% (9 of 42). This possibly
reflects the more aggressive inflammatory response in the
subarachnoid space in this group.14 Although cerebral
infarction on brain images was more common among
HIV-negative group in our cases, it is difficult to document
that the above finding is directly related to cryptococcal
meningitis, and less cerebral infarction occurring in HIV-
infected patients might be resulted from their younger age.
Generally, the 3-month mortality rate during manage-
ment of acute cryptococcal meningoencephalitis approxi-
mates 20% despite access to advanced medical care and the
availability of highly active antiretroviral therapy.19,20 In
HIV-negative patients, overall mortality rates have varied
from 9 to 31%.15,21,22 Beside, Sun et al.7 reported that the
mortality rate within 2 weeks and 10 weeks of hospitali-
zation with cryptococcosis was 10.3% and 20.7%, respec-
tively in HIV-infected patients responding to highly active
antiretroviral therapy. A higher proportion of patients in
the HIV-negative group died, which could be explained by
the longer delay in starting antifungal agents after arrival
at the hospital (9.5 days in HIV-negative group vs. 2.6 days
in HIV-positive group).
The poor prognostic factors for cryptococcal meningitis
reported by prior studies included (1) Cryptococcus growth
from sites other than CSF, (2) alteration in mental status, (3)
elevated opening pressure > 200 mmH2O, (4) CSF
glucose < 40 mg/dL, (5) CSF cell count < 20 cells/mm3, (6)
high CSF LACT titer,13,23,24 and (7) positive India ink
smear.12,25 Our data showed that altered mental status,
extraneural involvement, absence of CSF lymphocytepredominance, and absence of leptomeningeal enhance-
ment on brain images were independent risk factors for
30-day mortality, the former two factors comparable to
previous studies. Cryptococcal meningitis, an example of
chronic meningitis, is the most common cause of fungal
meningitis, and lymphocytic pleocytosis is usually presented
in CSF finding.26. Thus absence of CSF lymphocyte predomi-
nance on CSF finding might contribute to the delayed
administration of antifungal agents. There is no pathogno-
monic brain image of cryptococcal meningitis, and CT scans
or MRI may be normal or reveal meningeal enhancement,
single or multiple nodules (cryptococcomas), cerebral
edema or hydrocephalus.27 In our series, higher proportion of
patients with leptomeningeal enhancement on brain images
had received lumbar puncture within 3 days than those
without such a radiological finding (70.4% vs. 63.8%,
p Z 0.567), probably implicating that leptomeningeal
enhancement on brain images alerted the clinician for early
diagnosis of CNS infection. In the present study, initial serum
white count more than 11,000/mL, higher Charlson comor-
bidity score, and abnormal brain images were documented as
independent risk factors for 90-day mortality, which indi-
cated that underlying diseases (Charlson comorbidity score)
and severe inflammatory response either systemic or in
subarachnoid space14 (abnormal brain images) were impor-
tant. On the other hand, HIV infection doesnot play a role in
mortality at Day 30 and Day 90 in our cases, similar to the
previous study by Jean et al.28 But Ganiem et al.29 reported
that 1-month mortality was higher and strongly associated
with HIV infection in adult meningitis, including cryptococcal
meningitis, in Indonesia. This difference in mortality could
be explained by the fact that patients with HIV-positive
cryptococcal meningitis admitted at NTUH routinely receive
repeated lumbar puncture to relieve increased intracranial
pressure (IICP), as reported by Sun et al.30
As for management of cryptococcal meningitis, the
duration of induction therapy with amphotericin B in HIV-
infected and noneHIV-infected individuals was different (2
weeks vs. 4e6 weeks).31 Beside, objective of treatment in
either HIV-positive or HIV-negative cryptococcal meningitis
could be different, too. In HIV-positive cryptococcal
meningitis, control of elevated intracranial pressure,
long-term control of infection, and resolution of clinical
evidence of disease are the principal goals, although failing
eradication of this infection is common in HIV disease. In
HIV-negative cryptococcal meningitis, the goal of treat-
ment includes both (1) cure of the infection (CSF sterili-
zation) and (2) prevention of long-term CNS system
sequelae, such as cranial nerve palsies, hearing loss, and
blindness. In our cases, the information was not recorded
because of its retrospective entity.
There were limitations in the present study. First, our
study was a retrospective research by using secondary data
source (patients’ medical records). Usually there are
missing data and misclassification in this kind of study.
However, these factors would only make the results
become more conservative. Second, not all patients were
checked for HIV status because some patients died before
they could be screened for HIV, and HIV screening is still not
well accepted by Taiwanese. Third, flucytosine was
not available at NTUH in the past 10 years, so it was not
included in our study of its effect on mortality. Finally, it is
Comparisons of clinical features and mortality of cryptococcal meningitis 345difficult to confirm those patients with infarctions were
newly onset or old events because not all patients received
diffusion-weighted imaging of MRI.
In summary, our study demonstrated that among
patients with cryptococcal meningitis, those in HIV-positive
group were younger, more likely to be male gender, more
likely to have cough, more likely to have an initial serum
LACT exceeding 1:512, more likely to have extraneural
involvement, had higher Charlson comorbidity score, and
less likely to have abnormal brain images than those in
HIV-negative group. Altered mental status, extraneural
involvement, absence of CSF lymphocyte predominance,
and absence of leptomeningeal enhancement on brain
images were independent risk factors for 30-day mortality.
Serum white blood cell count of more than 11,000/mL,
Charlson comorbidity score, and absence of normal brain
images were documented as independent risk factors for
90-day mortality. Presence of HIV infection is not a risk
factor for 30-day, 90-day, and in-hospital mortality of
patients with cryptococcal meningitis.Acknowledgments
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